ESTRO 2025 - Abstract Book

S232

Brachytherapy - Gynaecology

ESTRO 2025

1595

Digital Poster Feasibility of Centralizing MR-Guided Brachytherapy for Locally Advanced Cervical Cancer in Austria Johannes Knoth 1 , Hazem Ramadan 1 , Eva M Weis 2 , Gebhard Kurzweil 3 , Bettina Celedin 4 , Oxana Komina 5 , Johanna Salinger 6 , Julia Böswarth 6 , Stephan Skorbier 7 , Michaela Buchegger 8 , Sigrid Flatz 9 , Michael Kopp 3 , Martina Metz 8 , Alexander de Vries 9 , Irene Wedrich 5 , Thomas Brunner 7 , Joachim Widder 1 , Andrea Reim 10 , Nicole Eder-Nesvacil 1 , Christian Kirisits 1 , Wolfgang Raunik 4 , Petra Georg 6 , Hans Geinitz 2 , Alina Sturdza 1 , Maximilian P Schmid 1 1 Department of Radiation Oncology, Comprehensive Cancer Center, Medical University Vienna/General Hospital of Vienna, Vienna, Austria. 2 Abteilung für Radioonkologie, Ordensklinikum Linz, Linz, Austria. 3 Fachbereich für Radiotherapie-Radioonkologie, Salzkammergut Klinikum, Vöcklabruck, Austria. 4 Institut für Strahlentherapie und Radioonkologie, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria. 5 Institut für Radioonkologie, Klinik Hietzing, Vienna, Austria. 6 Klinische Abteilung für Strahlentherapie – Radioonkologie, Universitätsklinikum Krems, Krems, Austria. 7 Universitätsklinik für Strahlentherapie - Radioonkologie, Comprehensive Cancer Center, Medical University Graz, Graz, Austria. 8 Klinisches Institut für Radioonkologie und Strahlentherapie, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria. 9 Abteilung für Radioonkologie und Strahlentherapie, Landeskrankenhaus Feldkirch, Feldkirch, Austria. 10 Zentrum für Radioonkologie und Strahlentherapie, Klinik Donaustadt, Vienna, Austria Purpose/Objective: Chemoradiotherapy including MRI-guided adaptive brachytherapy (BT) is the standard treatment for locally advanced cervical cancer. Due to expertise, logistic, and infrastructural challenges and staffing required for this treatment, centralizing BT care to high-volume reference centres appears advisable and is also recommended in the ESGO/ESTRO/ESP guidelines [1]. This study assesses the feasibility and oncological outcomes of centralizing BT in Austria. Material/Methods: Following ethical approval, this retrospective study included all patients with primary cervical cancer who received chemoradiotherapy at external clinics and were referred for BT to the main clinical and academic gyn BT facility in our region between 2018 and 2022. Primary endpoints were actuarial overall survival, local control, pelvic lymph node control, and disease-free survival assessed using the Kaplan-Meier method. Feasibility was assessed by measuring overall treatment time (OTT). Results: The study included 89 patients from 10 centres with a median age of 52 years (range 28-87). Stage distribution was T1b2 (7%), T2a (8%), T2b (55%), T3a (3%), T3b (20%), and T4 (7%). Histologically, 85% had squamous cell carcinoma, 13% adenocarcinoma, and 2% adenosquamous carcinoma. Lymph node metastases were present in 61% of patients, 17% had positive para-aortic nodes (see also table 1).